Pharmacopeia Agrees to Identify Lead Compounds for Boehringer Ingelheim | GenomeWeb

NEW YORK, Oct. 2 – Drug discovery company Pharmacopeia of Princeton, NJ, said Tuesday it has agreed to collaborate with German pharmaceutical company Boehringer Ingelheim to identify lead compounds for an undisclosed target.

Under the terms of the deal, Pharmacopeia will help Boehringer Ingelheim to develop assays and will provide the company with compound samples. In addition, Pharmacopeia will also provide high-throughput screening technology services.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.